TEVA: According to FDA News, Teva decided not to file Laquinimod NDA for relapsing remitting multiple sclerosis (RRMS) after discussion with FDA.
According to Teva's presentation at RBC, the FDA has agreed to an EDSS score primary endpoint for a new phase III study for Laquinimod (the BRAVO study, which failed to show statsig had an ARR primary endpoint).
Market Data 
Markets 
AI
